Journal Article

Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections

Sofizadeh, Sheyda, Tuomilehto, Jaako, Ólafsdóttir, Arndís F., Sjöberg, Stefan, Dahlqvist, Sofia, Filipsson, Karin, Hirsch, Irl, Ekelund, Magnus, Lind, Marcus, Ahrén, Bo, Imberg, Henrik

2019

Overview

Introduction The effects of the GLP-1 analogue liraglutide on time in hypoglycaemia, time in hyperglycaemia, and time in range for type 2 diabetes patients initially treated with multiple daily insulin injections (MDI) were investigated. Variables associated with hypoglycaemia in the current population were also identified. Methods Analyses were based on data from a previously performed double-blind, placebo-controlled trial in which 124 MDI-treated patients with type 2 diabetes were randomized to liraglutide or placebo. Masked continuous glucose monitoring (CGM) was performed at baseline and week 24 in 99 participants. Results The mean time in hypoglycaemia was similar for participants receiving liraglutide and those receiving placebo after 24 weeks of treatment. Mean time in target was greater in the liraglutide group than in the placebo group: 430 versus 244 min/24 h ( p  < 0.001) and 960 versus 695 min/24 h ( p  < 0.001) for the two glycaemic ranges considered, 4–7 mmol/l and 4–10 mmol/l, respectively. Mean time in hyperglycaemia was lower in the liraglutide group: 457 versus 723 min/24 h ( p  = 0.001) and 134 versus 264 min/24 h ( p  = 0.023) for the two cutoffs considered, > 10 mmol/l and > 14 mmol/l, respectively. Lower mean glucose level, lower C-peptide, and higher glucose variability were associated with an increased risk of hypoglycaemia in both treatment groups. Higher proinsulin level was associated with a lower risk of hypoglycaemia in the liraglutide group. Conclusion For type 2 diabetes patients initially treated with MDI, introducing liraglutide had a beneficial effect on glucose profiles estimated by masked CGM. Mean glucose level, glycaemic variability, C-peptide, and proinsulin level influenced the risk of hypoglycaemia in this population. Trial Registration ClinicalTrials.gov, number (EudraCT nr: 2012-001941-42). Funding Novo Nordisk funded this study. The Diabetes Research Unit, NU-Hospital Group funded the journal’s Rapid Service Fee.

• Publisher: Springer Healthcare,Springer,Springer Nature B.V
• Subject: Antidiabetics / Cardiology / Clinical Medicine / Continuous glucose monitoring / Diabetes / Dosage and administration / Drug therapy / Endocrinology / Endocrinology and Diabetes / Endokrinologi och diabetes / Evaluation / Glucose / Glucose monitoring / Hyperglycaemia / Hyperglycemia / Hypoglycaemia / Hypoglycemia / Injections / Insulin / Internal Medicine / Klinisk medicin / Liraglutide / Medical and Health Sciences / Medicin och hälsovetenskap / Medicine / Medicine & Public Health / Original Research / Peptides / Placebo / Randomized clinical trial / Time in range / Type 2 diabetes / Type 2 diabetes mellitus